Sankey It
Loading...
Johnson & Johnson FY2023 income statement | Sankey It
Sankey It · JNJ
Johnson & Johnson FY2023 income statement
USD · fiscal year ended 2023-12-31
FY2025
FY2024
FY2023
FY2022
FY2021
Quarterly
Annual
comfortable
compact
Hide amounts
Export
Fullscreen
Johnson & Johnson FY2023 income statement
Flow diagram with 10 nodes and 9 flows for Johnson & Johnson FY2023 income statement. Values: Innovative Medicine US$54.8B, MedTech US$30.4B, Revenue US$85.2B, Cost of Revenue US$26.6B, Gross Profit US$58.6B, Operating Expenses US$35.2B, Operating Income US$23.4B, Other Expense US$8.3B, Tax US$1.7B, Net Income US$35.2B.
Innovative Medicine
US$54.8B
64% of revenue
MedTech
US$30.4B
36% of revenue
Revenue
US$85.2B
+6% Y/Y
Cost of Revenue
(US$26.6B)
+8% Y/Y
31% of revenue
Gross Profit
US$58.6B
+6% Y/Y
69% margin
Operating Expenses
(US$35.2B)
+2% Y/Y
41% of revenue
Operating Income
US$23.4B
+11% Y/Y
27% margin
Other Expense
(US$8.3B)
+405% Y/Y
10% of revenue
Tax
(US$1.7B)
-42% Y/Y
2% of revenue
Net Income
US$35.2B
+96% Y/Y
41% margin
Net / profit
Inputs
Tax / cost
Copy link
Share on X
Open full screen